CSL shares (ASX: CSL) closed at A$138 today, marking an eight-year low and capping a brutal 12-month decline that has seen the biotechnology giant lose nearly half its market value amid a cascade of ...

The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring.  | The company is working with regulators to ensure stable ongoing supply for the one-time gene therapy ...

CSL Limited has provided an updated notification to the ASX on the progress of its on-market share buy-back program for ordinary fully paid shares. The update, dated 4 March 2026, reports that a total ...

ADRs of CSL Limited (OTCQX:CSLLY) dropped ~16% on Tuesday as Wall Street reacted to Australian biotech’s plans to lay off 15% of its workforce, announced in conjunction with its fiscal 2025 financials ...

CSL Limited has provided an updated notification to the ASX confirming continued execution of its on‑market share buy-back program for its ordinary fully paid shares. The company reported that a ...

The ASX biotech company has great growth potential this year. The post 3 reasons to buy CSL shares today appeared first on ...

Fintel reports that on December 8, 2025, JEFFERIES maintained coverage of CSL Limited - Depositary Receipt (OTCPK:CSLLY) with a Buy recommendation. As of December 6, 2025, the average one-year price ...

But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found ...

Market volatility has pushed a number of high-quality stocks lower. Here’s how I’m thinking about this. The post CSL and ...

Australia-headquartered CSL Limted broke ground Monday for the $1.5 billion expansion of its manufacturing facility in Kankakee, Illinois, USA.